Fort Bliss

Researchers are evaluating if adding LY3537982 olomorasib to standard anti-cancer drugs improves treatment for participants with untreated advanced non-small cell lung cancer NSCLC that has a specific KRAS G12C gene change. This Phase 3 treatment study includes participants with locally advanced or metastatic NSCLC and aims to compare this combination against standard care. The study is sponsored by Eli Lilly and Company and could last up to 3 years depending on individual response and disease progression. Participants receive LY3537982 orally combined with pembrolizumab given intravenously in 21-day cycles. Some groups also receive chemotherapy drugs pemetrexed and platinum cisplatin or carboplatin intravenously. There are different dose levels and combinations being tested, including placebo groups for comparison. Treatment continues until specific discontinuation criteria are met. Parts of the study are randomized and double-blinded, with some parts non-randomized for safety lead-in. During the study, participants have regular assessments including imaging scans to measure tumor response, blood tests, and questionnaires about symptoms and quality of life. Researchers monitor side effects and survival outcomes. The main measures include progression-free survival and treatment-emergent adverse events over about one year, with overall survival followed for up to three years. Participants are closely followed throughout treatment and after to evaluate the effects and safety of the study medications.

This research aims to evaluate the safety, effectiveness, and tolerability of two repetitive transcranial magnetic stimulation rTMS protocols targeting the dorsolateral prefrontal cortex to reduce depression symptoms in U.S. military members and veterans with a history of concussion or mild traumatic brain injury. The study uses a randomized, double-blind, Bayesian adaptive design to compare individualized connectome targeted accelerated intermittent Theta Burst Stimulation and scalp-targeted stimulation in this specific population. Participants are assigned randomly to one of three groups active rTMS with individualized connectome targeting, active rTMS with resting state functional MRI-based targeting, or a sham placebo rTMS group. These treatments are delivered as device-based brain stimulation therapies designed to assess their impact on depressive symptoms. The study includes an initial treatment phase followed by post-intervention assessments and a 6-month follow-up period. During the study, participants will undergo evaluations using the Montgomery-Asberg Depression Rating Scale to measure changes in depression symptoms from baseline through post-intervention and at 6 months. Additional assessments include self-reported depression scales, quality of life related to brain injury, PTSD symptoms, and brain connectivity via MRI scans. Researchers will monitor treatment compliance, adverse events, and overall safety throughout the trial, which lasts up to 6 months after final treatment.

Researchers are evaluating the feasibility of providing early access to mental healthcare during sarcoma treatment and how this early psychiatric care relates to depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma. The study is a randomized pilot designed to provide insights into mental health support for these patients. The research is led by Memorial Sloan Kettering Cancer Center and focuses on both bone and soft tissue sarcoma cases. Participants will be randomly assigned to one of two groups the Early Psychiatric Referral group or the No Referral group. Those in the referral group will be directed to the MSK Department of Psychiatry and Behavioral Sciences, while those in the no referral group will receive no psychiatric referral as part of the study. Specific psychiatric treatments are not dictated by the study beyond the referral process. During the study, participants will attend scheduled visits over a period of two years, during which researchers will track how many complete these visits. Assessments will include mental health status related to depression and anxiety, surgical outcomes, and patient satisfaction. The study aims to monitor the impact of early psychiatric involvement on overall quality of life for patients receiving surgical treatment for sarcoma.